Cytokinetics: Strong Story, But Valuation Leaves Limited Upside [Seeking Alpha]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Seeking Alpha
oHCM peak revenue is realistically $764M–$1.72B after royalties, supporting only 40–80% of current equity value at a 4x sales multiple. nHCM represents the primary upside lever, but risk-adjusted, discounted valuations yield a base case of only ~$0.7B due to clinical and adoption uncertainties. CYTK is a 'prove-it' story; current valuation assumes strong execution across oHCM, nHCM, and pipeline, leaving little room for error. Richard Drury/DigitalVision via Getty Images Introduction Cytokinetics ( CYTK ) has crossed into the commercial stage with aficamten's (branded MYQORZO) approval in oHCM. The product was launched in January, and the first real revenue quarter is the one ongoing now, with
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics (CYTK) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cytokinetics to Announce First Quarter Results on May 5, 2026GlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
- Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.MarketBeat
- Cytokinetics (CYTK) was upgraded by Barclays PLC to "strong-buy".MarketBeat
CYTK
Earnings
- 2/24/26 - Miss
CYTK
Sec Filings
- 4/21/26 - Form 4
- 4/17/26 - Form DEF
- 4/17/26 - Form ARS
- CYTK's page on the SEC website